In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.

●Consolidated net sales totaled 222,584 million yen, an increase of 20,793 million yen (10.3%) year-on-year. Sales in the Mobility & Imaging Business Unit, Fine Chemicals Business Unit, and Life Science Business Unit all outperformed the previous fiscal year.
●Consolidated operating income increased by 13,064 million yen (178.1%) to 20,401 million yen compared to the pre-vious fiscal year.
●Consolidated ordinary income totaled 22,266 million yen, an increase of 9,704 million yen (77.3%) year-on-year. The increase was due to growth in consolidated operating income which exceeded the decrease in foreign exchange gains.
●Profit attributable to owners of parent was 17,508 million yen, an increase of 13,395 million yen (325.6%) year-on-year. The increase was mainly due to a gain on sales of investment securities.

(Yen)	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03
Net income per share	96.09	90.23	89.45	85.77	74.25	73.62	101.70	89.36	24.80	107.17
Net assets per share	1,075.56	1,120.74	1,203.23	1,247.75	1,225.71	1,332.06	1,459.06	1,532.35	1,625.18	1,673.24
Dividend per share	30	30	30	30	30	30	40	45	45	60
Dividend payout ratio	31.2%	33.2%	33.5%	35.0%	40.4%	40.7%	39.3%	50.4%	181.5%	56.0%